Michael Schmidt
Stock Analyst at Guggenheim
(4.95)
# 25
Out of 5,147 analysts
118
Total ratings
73.91%
Success rate
54.96%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Schmidt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ONC BeOne Medicines AG | Maintains: Buy | $400 → $410 | $316.99 | +29.34% | 5 | Feb 27, 2026 | |
| GMAB Genmab | Maintains: Buy | $45 → $40 | $29.44 | +35.87% | 4 | Feb 23, 2026 | |
| TNGX Tango Therapeutics | Maintains: Buy | $12 → $18 | $11.14 | +61.58% | 2 | Feb 6, 2026 | |
| NBTX Nanobiotix | Maintains: Buy | $8 → $26 | $31.04 | -16.24% | 3 | Feb 6, 2026 | |
| RVMD Revolution Medicines | Maintains: Buy | $92 → $160 | $102.02 | +56.83% | 5 | Jan 20, 2026 | |
| CTMX CytomX Therapeutics | Initiates: Buy | $10 | $5.37 | +86.22% | 1 | Jan 20, 2026 | |
| GLUE Monte Rosa Therapeutics | Maintains: Buy | $16 → $34 | $17.75 | +91.55% | 2 | Jan 8, 2026 | |
| IMNM Immunome | Maintains: Buy | $25 → $35 | $21.86 | +60.11% | 4 | Dec 16, 2025 | |
| FHTX Foghorn Therapeutics | Initiates: Buy | $12 | $5.68 | +111.27% | 1 | Nov 7, 2025 | |
| INCY Incyte | Upgrades: Buy | $125 | $101.27 | +23.43% | 7 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $4.10 | +143.90% | 6 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $13.45 | +33.83% | 6 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $12 | $5.65 | +112.39% | 5 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $15 | $13.27 | +13.04% | 6 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $17 | $38.85 | -56.24% | 1 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $45 | $22.97 | +95.91% | 2 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $15 | $21.70 | -30.88% | 1 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $52 | $91.35 | -43.08% | 1 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $10 | $10.26 | -2.53% | 1 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $21.71 | +47.40% | 3 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $14 | $5.72 | +144.76% | 3 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $19.00 | - | 1 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $42 | $44.06 | -4.68% | 10 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $2.32 | - | 1 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $20 | $6.36 | +214.47% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $8 | $2.39 | +234.73% | 3 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $32.30 | - | 3 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $112 | $7.25 | +1,444.83% | 4 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.52 | - | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.99 | - | 2 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.78 | - | 1 | Jan 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $34 | $12.77 | +166.25% | 4 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $13.66 | +83.02% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $2.57 | +911.67% | 1 | May 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.88 | - | 2 | Apr 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $80 | $30.23 | +164.64% | 5 | Feb 15, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $7.58 | - | 6 | Jan 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $4 → $5.5 | $4.66 | +18.03% | 2 | Nov 7, 2017 |
BeOne Medicines AG
Feb 27, 2026
Maintains: Buy
Price Target: $400 → $410
Current: $316.99
Upside: +29.34%
Genmab
Feb 23, 2026
Maintains: Buy
Price Target: $45 → $40
Current: $29.44
Upside: +35.87%
Tango Therapeutics
Feb 6, 2026
Maintains: Buy
Price Target: $12 → $18
Current: $11.14
Upside: +61.58%
Nanobiotix
Feb 6, 2026
Maintains: Buy
Price Target: $8 → $26
Current: $31.04
Upside: -16.24%
Revolution Medicines
Jan 20, 2026
Maintains: Buy
Price Target: $92 → $160
Current: $102.02
Upside: +56.83%
CytomX Therapeutics
Jan 20, 2026
Initiates: Buy
Price Target: $10
Current: $5.37
Upside: +86.22%
Monte Rosa Therapeutics
Jan 8, 2026
Maintains: Buy
Price Target: $16 → $34
Current: $17.75
Upside: +91.55%
Immunome
Dec 16, 2025
Maintains: Buy
Price Target: $25 → $35
Current: $21.86
Upside: +60.11%
Foghorn Therapeutics
Nov 7, 2025
Initiates: Buy
Price Target: $12
Current: $5.68
Upside: +111.27%
Incyte
Nov 3, 2025
Upgrades: Buy
Price Target: $125
Current: $101.27
Upside: +23.43%
Aug 13, 2025
Reiterates: Buy
Price Target: $10
Current: $4.10
Upside: +143.90%
Aug 13, 2025
Reiterates: Buy
Price Target: $18
Current: $13.45
Upside: +33.83%
Aug 12, 2025
Maintains: Buy
Price Target: $10 → $12
Current: $5.65
Upside: +112.39%
Aug 7, 2025
Maintains: Buy
Price Target: $16 → $15
Current: $13.27
Upside: +13.04%
Jul 8, 2025
Reiterates: Buy
Price Target: $17
Current: $38.85
Upside: -56.24%
Jun 24, 2025
Reiterates: Buy
Price Target: $45
Current: $22.97
Upside: +95.91%
May 23, 2025
Maintains: Buy
Price Target: $40 → $15
Current: $21.70
Upside: -30.88%
May 12, 2025
Reiterates: Buy
Price Target: $52
Current: $91.35
Upside: -43.08%
May 7, 2025
Maintains: Buy
Price Target: $30 → $10
Current: $10.26
Upside: -2.53%
May 6, 2025
Reiterates: Buy
Price Target: $32
Current: $21.71
Upside: +47.40%
Mar 24, 2025
Maintains: Buy
Price Target: $13 → $14
Current: $5.72
Upside: +144.76%
Mar 12, 2025
Reiterates: Neutral
Price Target: n/a
Current: $19.00
Upside: -
Feb 12, 2025
Reiterates: Buy
Price Target: $42
Current: $44.06
Upside: -4.68%
Jan 22, 2025
Reiterates: Buy
Price Target: n/a
Current: $2.32
Upside: -
Dec 6, 2024
Reiterates: Buy
Price Target: $20
Current: $6.36
Upside: +214.47%
Nov 15, 2024
Maintains: Buy
Price Target: $12 → $8
Current: $2.39
Upside: +234.73%
Oct 7, 2024
Downgrades: Neutral
Price Target: n/a
Current: $32.30
Upside: -
Sep 30, 2024
Upgrades: Buy
Price Target: $112
Current: $7.25
Upside: +1,444.83%
May 15, 2024
Downgrades: Neutral
Price Target: n/a
Current: $4.52
Upside: -
Mar 14, 2024
Downgrades: Neutral
Price Target: n/a
Current: $4.99
Upside: -
Jan 5, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.78
Upside: -
Nov 8, 2023
Maintains: Buy
Price Target: $40 → $34
Current: $12.77
Upside: +166.25%
Aug 10, 2021
Initiates: Buy
Price Target: $25
Current: $13.66
Upside: +83.02%
May 18, 2021
Initiates: Buy
Price Target: $26
Current: $2.57
Upside: +911.67%
Apr 28, 2021
Downgrades: Neutral
Price Target: n/a
Current: $3.88
Upside: -
Feb 15, 2019
Upgrades: Outperform
Price Target: $80
Current: $30.23
Upside: +164.64%
Jan 17, 2019
Initiates: Outperform
Price Target: n/a
Current: $7.58
Upside: -
Nov 7, 2017
Maintains: Market Perform
Price Target: $4 → $5.5
Current: $4.66
Upside: +18.03%